被忽视的热带疾病治疗市场－全球产业规模、份额、趋势、机会、预测：按疾病、产品、地区和竞争对手划分，2021-2031年

全球被忽视的热带疾病 (NTD) 治疗市场预计将从 2025 年的 79.9 亿美元增长到 2031 年的 111.9 亿美元，复合年增长率达到 5.77%。

该市场涉及用于对抗热带地区流行感染疾病（例如土源性蠕虫病和淋巴丝虫病）的药品和医疗干预措施的研发和供应。该领域的成长主要得益于跨国製药公司的大规模药品捐赠计画以及支持研究和药品取得的慈善组织的大量资金投入。此外，政府主导的大规模药品管理倡议也提供了至关重要的基础，确保了对治疗药物的稳定需求，并保证了向高风险族群的系统性供应。

然而，许多流行地区的医疗基础设施不足，严重阻碍了市场扩张，并给偏远社区的「最后一公里」配送造成了严重的物流限制。这些供应链缺陷经常扰乱治疗计划，并限制了全球卫生计画的有效覆盖范围。根据国际药品製造商协会联合会（IFPMA）统计，2023年全球约有9亿人接受了被忽视的热带疾病治疗。这项数据凸显了在物流障碍持续存在的情况下，管理这些疾病所需的庞大营运规模。

市场驱动因素

世界卫生组织2030年蓝图及其根除目标的策略性实施将成为重要的市场催化剂，推动全球行动的重点从疾病控制转向彻底阻断传播。这项政策架构鼓励各国政府将被忽视的热带病防治项目纳入核心卫生系统，从而增加对认证所需的基本诊断工具和治疗方法的采购。蓝图强调可衡量的里程碑，因此需要持续满足治疗后监测技术的需求，并维持药品储备，直到确认根除为止。正如2024年12月发布的《携手抗击被忽视的热带病2024：年度回顾》报告所述，全球努力已取得重大进展，已有54个国家根除了至少一种被忽视的热带病，这巩固了市场向根除需求驱动型发展的方向。

此外，世界卫生组织增加的资金和津贴，以及强有力的公私合营，确保了资源匮乏地区药品生产和分发所需的流动资金。由于该领域的商业性回报有限，慈善资金和企业捐赠对于维持吡喹酮和阿苯达唑等关键药物的供应链至关重要。这些合作计画不仅资助新疗法的研究，还补贴大规模给药计画的物流成本，从而弥合生产和病患取得之间的差距。根据被忽视的热带疾病根除联盟于2024年10月发布的《基加利被忽视的热带疾病宣言：2022-2024年进展报告》，国际合作伙伴已筹集17亿美元用于实现这些目标。此外，卫材株式会社报告称，到2025年，已累计向流行地区提供了25.1亿片乙胺嗪片，这充分展现了企业为支持市场稳定所做的巨大贡献。

市场挑战

流行地区医疗基础设施的匮乏严重阻碍了被忽视的热带疾病（NTD）治疗药物全球市场的发展。这项挑战表现为严重的物流瓶颈，在基本药物到达最终目的地之前就造成了供应链中断。在许多受影响地区，缺乏可靠的运输网络、温控储存设施和设备齐全的当地诊所，阻碍了治疗药物的稳定供应。即使国际捐赠项目能够购买大量药品，这些基础设施的不足也常常导致当地仓库出现缺货和药品过期的情况。因此，市场无法将现有库存转化为实际的治疗，失去了维持全球卫生倡议所需的营运动力。

这些后勤保障方面的失误直接导致所需医疗干预规模与实际接受治疗的患者人数之间持续存在差距，使得很大一部分人口无法获得医疗保健，并限制了可覆盖的市场规模。根据世界卫生组织（世卫组织）2024年的报告，全球约有16.2亿人需要治疗被忽视的热带疾病（NTD）。这项数据凸显了当前很大一部分需求仍未满足的现状，这主要是由于缺乏提供医疗服务的必要手段，即便已有治疗方法。这种供不应求会降低大规模药物宣传活动的有效性，并阻碍未来的投资成长，从而抑制市场发展。

市场趋势

针对儿童适用的儿童製剂和剂型的研发正成为一项关键趋势，旨在解决流行地区幼儿治疗的不平等问题。传统上，由于缺乏适合学龄前儿童的药物选择，大规模用药宣传活动受到阻碍，常常导致成人药片被不准确地碾碎，从而影响安全性和用药依从性。如今，製药公司正优先研发可分散、口感良好的片剂，以确保剂量准确，并方便这一弱势族群服用。例如，默克公司在2025年3月发布的新闻稿《首次在学龄前儿童中使用阿普拉喹酮（一种儿童寄生虫病治疗药物）》中报告称，在乌干达的一项研究中，他们成功使用了新开发的可分散片剂，这表明市场在为儿童提供全面治疗方面取得了进展。

同时，产品开发伙伴关係（PDP）作为一种主要的研发模式，其蓬勃发展正在重塑创新格局，并有效规避了缺乏商业性奖励而限制私部门投资的问题。这些联盟将製药公司、学术机构和慈善组织的资源整合到一个虚拟的研究引擎中，成功地推动了新型化合物的发现和再利用。这种合作框架对于维持可行的治疗药物研发管线至关重要，而任何一家公司都无法独自承担这项重任。被忽视疾病药物研发倡议（DNDi）就是这一趋势的显着例证。该组织在2025年7月发布的2024年度报告中指出，其管理46个研发计划，其中21个项目致力于新型化学物质的辨识或开发。这凸显了PDP模式在确保未来治疗方法的优势。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：被忽视的热带疾病（NTDs）治疗全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型分类的疾病（登革热、狂犬病、沙眼、伯氏溃疡、尤斯氏症、痲疯病、南美锥虫病、利什曼原虫症病、土源性蠕虫病、其他）
  • 副产品（药品、疫苗）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美被忽视的热带疾病（NTDs）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲被忽视的热带疾病（NTDs）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区被忽视的热带疾病（NTDs）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲被忽视的热带疾病（NTDs）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲被忽视的热带疾病（NTDs）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：被忽视的热带疾病（NTDs）治疗的全球市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd
• Sanofi SA
• Bayer AG
• GlaxoSmithKline plc
• Novartis AG
• Pfizer, Inc.
• Eisai Co., Ltd.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Neglected Tropical Disease (NTD) Treatment Market is projected to expand from USD 7.99 billion in 2025 to USD 11.19 billion by 2031, achieving a compound annual growth rate of 5.77%. This market involves the creation and supply of pharmaceuticals and medical interventions aimed at combating communicable diseases common in tropical zones, such as soil-transmitted helminthiases and lymphatic filariasis. Growth in this sector is largely propelled by extensive medication donation programs organized by multinational pharmaceutical companies, along with significant financial support from philanthropic entities that subsidize research and access. Additionally, government-led mass drug administration initiatives serve as a crucial foundation, generating consistent demand for therapeutics and ensuring systematic delivery to at-risk populations.

However, market expansion is significantly hindered by the inadequacy of healthcare infrastructure in many endemic regions, which imposes severe logistical constraints on last-mile delivery to isolated communities. These supply chain deficiencies frequently interrupt treatment schedules and restrict the effective reach of global health programs. According to the International Federation of Pharmaceutical Manufacturers & Associations, approximately 900 million individuals worldwide received treatment for a neglected tropical disease in 2023. This statistic underscores the immense operational scale required to manage these conditions, despite the persistent logistical obstacles complicating delivery efforts.

Market Driver

The strategic execution of the WHO 2030 Roadmap and Eradication Targets serves as a primary market catalyst, shifting the global operational focus from disease control to the complete interruption of transmission. This policy framework encourages national governments to incorporate NTD programs into their core health systems, thereby increasing the procurement of essential diagnostic tools and therapeutic regimens required for certification. The roadmap's emphasis on measurable milestones necessitates sustained demand for post-treatment surveillance technologies and the maintenance of medication stockpiles until elimination is verified. As reported by Uniting to Combat NTDs in their '2024: A year in review' released in December 2024, the global initiative achieved a critical milestone with 54 countries having eliminated at least one neglected tropical disease, confirming the market's trajectory toward eradication-driven demand.

Furthermore, increasing funding and grants from global health organizations, combined with robust public-private partnerships, provide the necessary financial liquidity for drug production and distribution in low-resource settings. Since commercial returns in this sector are limited, philanthropic capital and corporate donations are essential for sustaining the supply chain of critical medications like praziquantel and albendazole. These collaborative ventures not only finance research for new therapeutics but also subsidize the logistical costs of mass drug administration, bridging the gap between manufacturing and patient access. According to the 'Kigali Declaration on Neglected Tropical Diseases: 2022-2024 Progress Report' published by Uniting to Combat NTDs in October 2024, international partners have mobilized US$1.7 billion to support these goals. Additionally, Eisai Co., Ltd. reported in 2025 that it had provided a cumulative total of 2.51 billion diethylcarbamazine tablets to endemic regions, illustrating the vast scale of corporate contribution underpinning market stability.

Market Challenge

The deficiency of healthcare infrastructure in endemic regions constitutes a significant barrier to the growth of the Global Neglected Tropical Disease (NTD) Treatment Market. This challenge manifests as a severe logistical bottleneck where the supply chain for essential pharmaceuticals fractures before reaching the last mile. In many target areas, the absence of reliable transportation networks, climate-controlled storage facilities, and adequately equipped local clinics obstructs the consistent distribution of therapeutics. Even when international donation programs successfully mobilize vast quantities of medication, these infrastructure deficits frequently result in stockouts or product expiration at regional depots. Consequently, the market struggles to convert available inventory into administered treatments, stalling the operational momentum required to sustain global health initiatives.

The direct impact of these logistical failures is a persistent disconnect between the volume of medical interventions required and the actual number of patients served, which limits the addressable market size by rendering a significant portion of the population inaccessible. According to the World Health Organization, it was reported in 2024 that approximately 1.62 billion people globally required interventions for neglected tropical diseases. This statistic highlights that, despite the availability of treatments, a massive segment of the demand remains unmet primarily due to the inability to physically deliver care. This delivery shortfall impedes market expansion by reducing the efficacy of mass drug administration campaigns and discouraging the scaling of future investments.

Market Trends

The development of pediatric-specific formulations and child-friendly dosage forms is emerging as a crucial trend, addressing a historical treatment gap for younger demographics in endemic regions. Previously, mass drug administration campaigns were hindered by a lack of suitable options for preschool-aged children, often requiring the inaccurate crushing of adult tablets, which compromised safety and adherence. Pharmaceutical manufacturers are now prioritizing the engineering of dispersible, palatable tablets that ensure precise dosing and ease of administration for this vulnerable group. For instance, in March 2025, Merck announced in the press release 'First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis' that its newly developed dispersible tablet was successfully administered in an implementation study in Uganda, validating the market's progression toward inclusive therapeutic coverage for pediatric populations.

Simultaneously, the proliferation of Product Development Partnerships (PDPs) as the primary R&D model is structurally reshaping the innovation landscape, effectively circumventing the limited commercial incentives that restrict private sector investment. By consolidating resources from pharmaceutical companies, academic institutions, and philanthropic entities into a virtual research engine, these consortia are successfully driving the discovery of novel compounds and repurposing strategies. This collaborative framework is essential for maintaining a viable pipeline of therapeutics that individual corporations cannot sustain in isolation. Highlighting this trend, the Drugs for Neglected Diseases initiative (DNDi) noted in its '2024 Annual Report' released in July 2025 that it managed a diverse portfolio of 46 R&D projects, with 21 specifically focused on identifying or developing new chemical entities, underscoring the dominance of the PDP model in securing future treatments.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Bayer AG
• GlaxoSmithKline plc
• Novartis AG
• Pfizer, Inc.
• Eisai Co., Ltd.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.

Report Scope

In this report, the Global Neglected Tropical Disease (NTD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Disease (NTD) Treatment Market, By Disease

• Dengue
• Rabies
• Trachoma
• Buruli Ulcer
• Yaws
• Leprosy
• Chagas Disease
• Leishmaniasis
• Soil-transmitted Helminthiases
• Others

Neglected Tropical Disease (NTD) Treatment Market, By Product

• Drugs
• Vaccines

Neglected Tropical Disease (NTD) Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Disease (NTD) Treatment Market.

Available Customizations:

Global Neglected Tropical Disease (NTD) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Disease (NTD) Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, Others)
  • 5.2.2. By Product (Drugs, Vaccines)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Neglected Tropical Disease (NTD) Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Product

7. Europe Neglected Tropical Disease (NTD) Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Product
  • 7.3.2. France Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Product

8. Asia Pacific Neglected Tropical Disease (NTD) Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Product
  • 8.3.2. India Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease
      • 8.3.5.2.2. By Product

9. Middle East & Africa Neglected Tropical Disease (NTD) Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Product

10. South America Neglected Tropical Disease (NTD) Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Neglected Tropical Disease (NTD) Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neglected Tropical Disease (NTD) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Bayer AG
• 15.4. GlaxoSmithKline plc
• 15.5. Novartis AG
• 15.6. Pfizer, Inc.
• 15.7. Eisai Co., Ltd.
• 15.8. Astellas Pharma Inc.
• 15.9. Takeda Pharmaceutical Company Limited
• 15.10. Gilead Sciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer